Affimed’s AFM24 Dose Optimization Abstract Accepted for AACR Poster Presentation
Manchester, NH, USA, March 25, 2025 – Affimed N.V., a pioneering immuno-oncology company, is thrilled to share that an abstract detailing the dose optimization of their lead investigational therapeutic, AFM24, using exposure response analysis, has been accepted for presentation as a poster at the prestigious Annual Meeting of the American Association for Cancer Research (AACR). The event will take place from April 25-30, 2025, in Chicago, Illinois.
About Affimed and AFM24
Affimed N.V. is a clinical-stage immuno-oncology company with a mission to restore the natural ability of patients’ immune systems to fight cancer. The company’s proprietary technology, called “Epitope-Diverse T-cell Engagers” (EpTCells), is designed to enhance the power of the immune system to recognize and eliminate cancer cells. AFM24 is one of Affimed’s EpTCells, targeting CD123, which is overexpressed on leukemic cells in various hematological malignancies.
The Poster Presentation
The accepted abstract focuses on optimizing the dosing regimen of AFM24 by analyzing the exposure-response relationship. This analysis is crucial for determining the optimal dose that maximizes efficacy while minimizing potential side effects. The study aims to provide valuable insights into the therapeutic potential of AFM24, potentially paving the way for more effective cancer treatments.
Impact on Individuals
For individuals battling hematological malignancies, the findings from this study could lead to improved treatment options. If AFM24 is found to be effective at the optimized dose, it could provide a new hope for patients who have limited or no response to current therapies. The results of this study could also influence the development of new combination therapies, further broadening the treatment landscape for various types of hematological malignancies.
Global Implications
The potential impact of this research extends beyond individual patients. If the optimized dose of AFM24 proves to be effective, it could contribute significantly to the advancement of immuno-oncology as a whole. The development of more effective cancer treatments could lead to a reduction in healthcare costs associated with managing various hematological malignancies. Moreover, it could inspire further research into the potential of EpTCells and other immunotherapies in the fight against cancer.
Conclusion
Affimed’s acceptance of an abstract detailing the dose optimization of AFM24 at the AACR Annual Meeting represents an essential step forward in the quest to develop more effective cancer treatments. The findings from this study could significantly impact individuals diagnosed with hematological malignancies, providing new hope for a potentially curative therapy. Furthermore, the global implications of this research could inspire further advancements in the field of immuno-oncology, ultimately contributing to a reduction in healthcare costs and a brighter future for cancer patients.
- Affimed’s AFM24 abstract accepted for AACR poster presentation
- Focuses on optimizing AFM24 dose using exposure-response analysis
- Potential to improve treatment options for hematological malignancies
- Could inspire new combination therapies
- Significant impact on individuals and the global cancer community
